According to a recent Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment, initiation of beta-blockers is often better tolerated when the patient is less congested ("dry"), with an adequate resting heart rate, while ARNI/ACEI/ARB is usually better tolerated when the patient is still congested ("wet"). Based on a study of Medicare beneficiaries, patients treated with one of the three evidence-based beta-blockers—carvedilol, bisoprolol, or sustained-release metoprolol succinate—had lower heart failure readmission and mortality rates.
Beta-blockers are recommended by the AHA/ACC/HFSA in all patients when HFrEF is diagnosed, unless contraindicated, to reduce mortality. Therapy should be initiated at a low dose and increased every 2 weeks until the target dose is achieved or until a dose increase is limited.
Beta-blocker use in patients with acute decompensated heart failure has been associated with "acute negative inotropic effects."
Learn more about the treatment of HFrEF.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Alanna Morris, Michael Weber, Jeffrey J. Hsu. Fast Five Quiz: Heart Failure With Reduced Ejection Fraction (HFrEF) Treatment Optimization - Medscape - Nov 16, 2023.